Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18664289 | ELECTROCARDIOGRAM (ECG) SIGNAL CLASSIFICATION METHOD BASED ON CONTRASTIVE LEARNING AND MULTI-SCALE FEATURE EXTRACTION | May 2024 | March 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18623075 | SYSTEM AND METHOD FOR DETECTION OF A HEART FAILURE RISK | April 2024 | May 2025 | Allow | 13 | 3 | 0 | No | No |
| 18595379 | GENERAL MULTI-DISEASE PREDICTION SYSTEM BASED ON CAUSAL CHECK DATA GENERATION | March 2024 | June 2025 | Abandon | 16 | 2 | 0 | No | No |
| 18414296 | IDENTIFICATION OF PATIENT SUB-COHORTS AND CORRESPONDING QUANTITATIVE DEFINITIONS OF SUBTYPES AS A CLASSIFICATION SYSTEM FOR MEDICAL CONDITIONS | January 2024 | December 2024 | Allow | 11 | 2 | 0 | Yes | No |
| 18405529 | System and Method to Facilitate Interoperability of Health Care Modules | January 2024 | January 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18460079 | SYSTEMS AND METHODS FOR REMOTE CONTROLLED ORTHODONTIC TREATMENT | September 2023 | May 2025 | Allow | 21 | 3 | 0 | Yes | No |
| 18228607 | GENERATING SKINCARE PRODUCT RECOMMENDATIONS FOR A USER BASED ON SKINCARE PRODUCT ATTRIBUTES AND USER LOCATION AND DEMOGRAPHIC DATA | July 2023 | January 2025 | Allow | 18 | 2 | 0 | No | No |
| 18217115 | APPARATUS AND METHOD FOR DETERMINING A COMPOSITION OF A REPLACEMENT THERAPY TREATMENT | June 2023 | July 2024 | Allow | 13 | 2 | 0 | Yes | No |
| 18214476 | METHODS AND SYSTEMS FOR CAUSATIVE CHAINING OF PROGNOSTIC LABEL CLASSIFICATIONS | June 2023 | May 2025 | Allow | 22 | 3 | 0 | Yes | No |
| 18035811 | METHODS AND RELATED ASPECTS FOR ANALYZING CHROMOSOME NUMBER STATUS | May 2023 | February 2025 | Allow | 21 | 4 | 0 | Yes | No |
| 18125673 | ARTIFICIAL INTELLIGENCE FOR IDENTIFYING ONE OR MORE PREDICTIVE BIOMARKERS | March 2023 | February 2025 | Allow | 22 | 5 | 0 | Yes | No |
| 18082344 | SYSTEMS AND METHODS FOR MODEL-ASSISTED DATA PROCESSING TO PREDICT BIOMARKER STATUS AND TESTING DATES | December 2022 | June 2025 | Allow | 30 | 4 | 0 | Yes | No |
| 17921383 | SECURE SYSTEM FOR MONITORING AND DISPENSING DOSES OF ACTIVE SUBSTANCES PRE-DETERMINED BY AN EXPERT AND CUSTOMISED FOR USERS | October 2022 | November 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17643165 | DATA ASSESSMENT AND VISUALIZATION PLATFORM FOR USE IN A NETWORK ENVIRONMENT INCLUDING COMPUTING DEVICES | December 2021 | June 2025 | Abandon | 42 | 2 | 0 | No | No |
| 17508877 | DEVICE AND METHOD FOR DETERMINING A LEVEL OR CONCENTRATION OF AN ANALYTE IN A PERSON'S BLOOD FROM ONE OR MORE VOLATILE ANALYTES IN THE PERSON'S BREATH | October 2021 | December 2024 | Allow | 38 | 1 | 1 | No | No |
| 17450114 | Systems and Methods for a Personal Diagnostic Device | October 2021 | February 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17420405 | METHOD FOR PERFORMING COMPLEX COMPUTING ON VERY LARGE SETS OF PATIENT DATA | July 2021 | June 2025 | Abandon | 47 | 4 | 0 | Yes | No |
| 17419459 | HEALTH ADMINISTRATION METHOD, APPARATUS, AND SYSTEM, AND DATA COLLECTION APPARATUS | June 2021 | January 2025 | Allow | 42 | 3 | 0 | Yes | No |
| 17223861 | Systems and Methods for Real-Time Bio-Risk Determination | April 2021 | October 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17215153 | INTEGRATED SYSTEMS AND METHODS FOR EVOLVING STATE PROTOCOLS AND DECISION SUPPORT | March 2021 | June 2024 | Allow | 39 | 4 | 0 | Yes | No |
| 17250824 | SYSTEM AND METHOD OF TREATING A PATIENT BY A HEALTHCARE PROVIDER USING A PLURALITY OF N-OF-1 MICRO-TREATMENTS | March 2021 | December 2024 | Abandon | 46 | 2 | 0 | No | No |
| 17183118 | SYSTEMS AND METHODS FOR MITIGATING THE SPREAD OF INFECTIOUS DISEASES | February 2021 | June 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17139014 | INQUIRY RECOMMENDATION FOR MEDICAL DIAGNOSIS | December 2020 | June 2025 | Abandon | 53 | 4 | 1 | Yes | No |
| 17043629 | DEEP LEARNING-BASED METHODS, DEVICES, AND SYSTEMS FOR PRENATAL TESTING | September 2020 | February 2024 | Abandon | 41 | 1 | 0 | No | No |
| 16978066 | HAND HELD COMMUNICATION DEVICE | September 2020 | November 2024 | Allow | 51 | 4 | 0 | No | No |
| 16995749 | DEVICE AND METHOD FOR MEDICAL DIAGNOSTICS | August 2020 | November 2024 | Allow | 51 | 4 | 1 | No | No |
| 16967620 | DIABETES RISK EARLY WARNING SYSTEM | August 2020 | March 2025 | Abandon | 56 | 4 | 1 | Yes | No |
| 16359778 | APPARATUS, SYSTEM AND METHOD FOR DATA DIFFUSION IN A MEDICAL COMPUTER SYSTEM | March 2019 | February 2025 | Abandon | 60 | 6 | 0 | Yes | Yes |
| 15913780 | SYSTEMS AND METHODS FOR CREATING AN EXPERT-TRAINED DATA MODEL | March 2018 | December 2024 | Abandon | 60 | 4 | 1 | No | Yes |
| 15061299 | Advanced Telemedicine System with Virtual Doctor | March 2016 | September 2019 | Allow | 43 | 3 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PATEL, JAY M.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PATEL, JAY M works in Art Unit 3681 and has examined 25 patent applications in our dataset. With an allowance rate of 56.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner PATEL, JAY M's allowance rate of 56.0% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PATEL, JAY M receive 2.92 office actions before reaching final disposition. This places the examiner in the 94% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by PATEL, JAY M is 41 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +35.1% benefit to allowance rate for applications examined by PATEL, JAY M. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.8% of applications are subsequently allowed. This success rate is in the 24% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 11.8% of cases where such amendments are filed. This entry rate is in the 6% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 18% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 1% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 36% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 36% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.